lvcandy/iStock via Getty Images
Regencell Bioscience (NASDAQ:RGC), a Hong Kong-based biopharma focused on traditional Chinese medicine, resumed its meteoric rise on Monday after the company’s previously announced 38-for-1 stock split took effect.
RGC had recorded over a 145-fold YTD jump amid volatility driven by